SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
Malaria treatment: Halofantrine
Read more from SRI
-
Researchers aim to disrupt how new materials are leveraged in the design process
SRI chosen by DARPA to develop next-generation computational design of metallic parts and intelligent testing of alloys.
-
Podcast: How students can help drive educational innovation
SRI’s Ela Joshi discusses how product developers, researchers, districts, and schools can leverage student voice.
-
SRI researchers develop rugged, low-cost, drifting sensors to learn more about the oceans
PEARL drifters pack an array of sensors into a compact autonomous device to gather data and signs of activity.